Transthyretin cardiac amyloidosis: Pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction

Clinical Medicine Insights: Cardiology

Volumn 8, Issue , 2015, Pages 39-44

  Ton, Van Khue ^a   Mukherjee, Monica ^a   Judge, Daniel P ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cardiac amyloidosis; Heart failure with preserved ejection fraction (HFpEF); Transthyretin (TTR)

Indexed keywords

AMYLOID; ANTISENSE OLIGONUCLEOTIDE; DIFLUNISAL; DOXYCYCLINE; EPIGALLOCATECHIN GALLATE; PLACEBO; PREALBUMIN; RESVERATROL; SMALL INTERFERING RNA; TAFAMIDIS; TETRAMER;

CYTOTOXICITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; GENDER; GENE MUTATION; HEART AMYLOIDOSIS; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; ONSET AGE; ORGAN TROPISM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROTEIN CONFORMATION; PROTEIN MISFOLDING; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TROPISM; TTR GENE;

EID: 84962885932     PISSN: None     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S15712     Document Type: Review

References (54)

1. Dungu JN, Anderson LJ, Whelan CJ, Hawkins PN. Cardiac transthyretin amyloidosis. Heart. 2012;98(21):1546–54
2. Coelho T, Maurer MS, Suhr OB. THAOS – the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63–76
3. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet. 1990;47(1):127
4. Yamashita T, Asl KH, Yazaki M, Benson MD. A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population. Amyloid. 2005;12(2):127–30
5. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466–73
6. Buxbaum J, Alexander A, Koziol J, Tagoe C, Fox E, Kitzman D. Significance of the amyloidogenic transthyretin Val122Ile allele in African Americans in the arteriosclerosis risk in communities (ARIC) and cardiovascular health (CHS) studies. Am Heart J. 2010;159(5):864–70
7. Buxbaum J, Jacobson DR, Tagoe C, et al. Transthyretin V122I in African Americans with congestive heart failure. J Am Coll Cardiol. 2006;47(8):1724–5
8. Jacobson D, Tagoe C, Schwartzbard A, Shah A, Koziol J, Buxbaum J. Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African American men. Am J Cardiol. 2011;108(3):440–4
9. Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the transthyretin amyloidosis cardiac study (TRACS). Am Heart J. 2012;164(2):222–228
10. Bishu K, Redfield MM. Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. Curr Heart Fail Rep. 2013;10(3):190
11. Shah AM, Pfeffer MA. The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2012;9(10):555
12. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113–22
13. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126(10):1286–300
14. Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013;22(3):189–94
15. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995;268(5213):1039–41
16. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J Mol Biol. 1978;121(3):339–56
17. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31
18. Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The transthyretin amyloidosis outcomes survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013;29(1):77–84
19. Penchala SC, Connelly S, Wang Y, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA. 2013;110(24):9992–7
20. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398–408
21. Jacobson DR, McFarlin DE, Kane I, Buxbaum JN. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement. Hum Genet. 1992;89(3):353–6
22. Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73–85
23. Sato T, Susuki S, Suico MA, et al. Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J. 2007;26(10):2501–2512
24. Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced end-glycation products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest. 2000;80(7):1101–1110
25. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res. 2010;106(5):842–853
26. Teixeira PF, Cerca F, Santos SD, Saraiva MJ. Endoplasmic reticulum stress associated with extracellular aggregates: evidence from transthyretin deposition in familial amyloid polyneuropathy. J Biol Chem. 2006;281(31):21998–2003
27. Santos S, Cardoso I, Magalhães J, Saraiva M. Impairment of the ubiquitin– proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. J Pathol. 2007;213(2):200–209
28. Liepnieks JJ, Wilson DL, Benson MD. Biochemical characterization of vitreous and cardiac amyloid in Ile84Ser transthyretin amyloidosis. Amyloid. 2006;13(3):170–7
29. Tasaki M, Ueda M, Obayashi K, et al. Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach. Int J Cardiol. 2013;170(1):69–74
30. Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid: a clinicopathologic correlation. Am J Med. 1983;75(4):618–23
31. Zhao L, Buxbaum JN, Reixach N. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry. 2013;52(11):1913–26
32. Begin ME, Langlois MF, Lorrain D, Cunnane SC. Thyroid function and cognition during aging. Curr Gerontol Geriatr Res. 2008;2008:1–11
33. Morinobu T, Tamai H, Tanabe T, et al. Plasma alpha-tocopherol, beta-carotene, and retinol levels in the institutionalized elderly individuals and in young adults. Int J Vitam Nutr Res. 1994;64(2):104–8
34. Kyle RA, Spittell PC, Gertz MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996;101(4):395–400
35. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain – associated amyloidosis. Arch Intern Med. 2005;165(12):1425–9
36. Gonçalves I, Alves CH, Quintela T, et al. Transthyretin is up-regulated by sex hormones in mice liver. Mol Cell Biochem. 2008;317(1–2):137–42
37. Hammarström P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293(5539):2459–62
38. Berk JL, Suhr OB, Obici L et al. Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658
39. Castaño A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012;18(6):315–9
40. Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109(24):9629–34
41. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92
42. Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6(6):1011–20
43. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid. 2007;14(4):277–82
44. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–7
45. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819–29
46. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012;19:43–4
47. Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Ther. 2014;39(3):225–33
48. Gonçalves NP, Vieira P, Saraiva MJ. Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid. 2014;21:1–10
49. Sinha S, Lopes DHJ, Du Z, et al. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc. 2011;133(42):16958–69
50. Ferreira N, Pereira-Henriques A, Attar A, et al. Molecular tweezers targeting transthyretin amyloidosis. Neurotherapeutics. 2014;11(2):450–61
51. Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun. 2011;410(4):707–13
52. Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva M. Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med. 2010;8(1):74
53. Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006;20:234–9
54. Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: “in vivo” evidence from FAP mice models. PLoS One. 2012;7(1):e29933.